The first, recently published, phase I clinical trial (AUGMENT-101 (NCT04065399)) on revumenib (previously known as SNDX-5613), a selective oral inhibitor of the menin–KMT2A interaction, investigated the effect of this drug in R/R AML. This evidence concerns the gene MEN1 and acute myeloid leukemia.